Serum ferritin has correlation with HbA1c in type 2 diabetic patients

Momeni, Ali; Behrad Manesh, Mohammad Saeed; Kheiri, Soleiman; Abasi, Fatemeh

Serum ferritin has correlation with HbA1c in type 2 diabetic patients

Authors

¹ Department of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

² Clinical Biochemistry Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

³ Medical School, Shahrekord University of Medical Sciences, Shahrekord, Iran

Abstract

Background: Serum C-reactive protein (CRP) and ferritin are two acute phase reactants. CRP may be related to metabolic syndrome and ferritin which in turn could cause resistance to insulin and dysfunction of b cells of pancreases. The aim of the study was the evaluation of the relationship of these two acute phase reactants with some indices of diabetic control.
Materials and Methods: In a quasi-experimental study, 67 patients with type 2 diabetes, serum CRP, ferritin, Fasting Blood Sugar (FBS), post prandial BS, Hemoglobin A1c (HbA1c), triglyceride, Low Density Lipoprotein Cholesterol (LDL) and High Density Lipoprotein cholesterol (HDL) were checked before and 3 months after the control of hyperglycemia and hyperlipidemia.
Results: The mean age of the patients was 56.5 ± 9.7 (30 to 82) years. There was no significant difference between CRP before and after study; however, serum ferritin significantly decreased after study with control of hyperglycemia. FBS, 2 hours post-prandial blood sugar (2hppBS), HbA1c and triglyceride of patients decreased significantly after control of hyperglycemia and hyperlipidemia (P < 0.05); however, HDL and LDL cholesterol didn't change (P > 0.05).
Conclusion: Based on our results, serum ferritin decreased after decline of patients' blood sugar, so might be we used it as one of the diabetes control indices for diabetic patients.

Keywords

References

1.	Hughes E, McCracken M, Roberts H, Mokdad AH, Valluru B, Goodson R, et al. Surveillance for certain health behaviors among states and selected local areas--behavioral risk factor surveillance system, United States, 2004. MMWR Surveill Summ 2006;55:1-124.
2.	McKinlay J, Marceau L. US public health and the 21 ^st century: Diabetes mellitus. Lancet 2000;356:757-61.
3.	Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
4.	Freid VM, Prager K, MacKay AP, Xia H. Chartbook on Trends in the Health of Americans. Health, United States, 2003. Hyattsville, Maryland: National Center for Health Statistics; 2003.
5.	Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-101.
6.	Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D'Agostino RB Sr. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: The Framingham Heart Study. Circulation 2006;113:2914-8.
7.	Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41:1241-8.
8.	Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: Results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003;163:93-9.
9.	Festa A, D'Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001;25:1407-15.
10.	Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-600.
11.	Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004;53:693-700.
12.	Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003;26:1745-51.
13.	Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987;84:7251-5.
14.	Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest 1987;79:1635-41.
15.	Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389:39-48.
16.	Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity. Science 1999;284:1313-8.
17.	Theil EC. Ferritin: Structure, gene regulation and cellular function in animals, plants, and microorganisms. Annu Rev Biochem 1987;56:289-315.
18.	Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004;27:2422-8.
19.	Ashourpour M, Djalali M, Djazayery A, Eshraghian MR, Taghdir M, Saedisomeolia A. Relationship between serum ferritin and inflammatory biomarkers with insulin resistance in a Persian population with type 2 diabetes and healthy people. Int J Food Sci Nutr 2010;61:316-23.
20.	American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33 Suppl 1:S62.
21.	Ebrahimi MM, Tohidi M, Hadaegh F, Azizi F. Role of C - reactive protein in prediction of type 2 diabetes (Tehran lipid and glucose study). Iran J Endocrinol Metab 2008;10:11-6.
22.	Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 1999;22:1978-83.
23.	Wrede CE, Buettner R, Bollheimer LC, Scholmerich J, Palitzsch KD, Hellerbrand C. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol 2006;154:333-40.

Advanced Biomedical Research